


CLAIMS

1. A compound of formula (I):



wherein:

Ar is phenyl which can be optionally substituted by one or more groups selected from halogen, hydroxy, cyano, C₁-C₈ alkyl (itself optionally substituted by one or more hydroxy or cyano groups or fluorine atoms), CH₂-R²; CH₂O(CH₂)_nOC₁₋₆ alkyl, C₁-C₈ alkyl-NR³-R⁴;

10 R² is a 5 to 7-membered saturated ring containing 1 or 2 heteroatoms selected from nitrogen, oxygen and sulphur, an aryl or 5- to 7-membered heteroaryl group containing 1 to 15 3 heteroatoms selected from nitrogen oxygen and sulphur, each of which can optionally substituted by one or more substituents selected from hydroxyl or hydroxymethyl;

R³ is hydrogen or C₁₋₆ alkyl and R⁴ is C₁₋₆ alkyl optionally substituted by one or more groups selected from hydroxyl or phenyl,

20

n is 1 to 4;

25 R¹ is hydrogen or phenyl optionally substituted by halogen, C₁-C₈ alkoxy, C₁-C₈ thioalkyl or C₁-C₈ alkyl;

and pharmaceutically acceptable salts thereof.

30 2. A compound according to claim 1 in which R¹ is hydrogen or phenyl optionally substituted by halogen, in particular fluoro or bromo.

3. A compound according to claim 1 or 2 in which Ar is a phenyl or a group CH_2R^2 where R^2 is pyrrolidine, morpholine or imidazole each of which is optionally substituted as defined in claim 1

5 4. A compound according to claim 1 or 2 in which Ar is a group CH_2R^2 where R^2 is pyrrolidine, morpholine or imidazole each of which is optionally substituted by hydroxyl or hydroxymethyl, $\text{CH}_2\text{NR}^3\text{-R}^4$ where R^3 is hydrogen or methyl and R^4 is $\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2(\text{CH}_3)\text{CH}_2\text{OH}$, $\text{CH}_2(\text{phenyl})\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2(\text{OH})\text{phenyl}$, $\text{CH}_2\text{CH}_2(\text{OH})\text{CH}_2\text{OH}$, or $\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_2\text{OH}$ or Ar is phenyl optionally substituted by one or more ethyl or 10 hydroxymethyl groups.

15 5. A compound according to any one of claims 1 to 3 in which the Ar group is substituted by $\text{C}_1\text{-C}_8$ alkyl and $\text{C}_1\text{-C}_8$ alkyl substituted by a hydroxy group, more preferably hydroxymethyl.

6. A compound according to claim 1 which is:

4-(2-Ethyl-phenylamino)-2-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

20 4-(2-Ethyl-3-hydroxymethyl-phenylamino)-2-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(2-hydroxy-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-[(2-hydroxy-ethyl)-methyl-amino]-methyl)-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

25 4-{2-Ethyl-3-[(2-hydroxy-1-methyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(S)-(2-hydroxy-1-phenyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

30 4-(2-Ethyl-3-[(2-hydroxy-2-phenyl-ethylamino)-methyl]-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-morpholin-4-ylmethyl-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-[2-Ethyl-3-(3-hydroxy-pyrrolidin-1-ylmethyl)-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-[2-Ethyl-3-((*R*)-2-hydroxymethyl-pyrrolidin-1-ylmethyl)-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

5 4-{3-[(2,3-Dihydroxy-propylamino)-methyl]-2-ethyl-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-imidazol-1-ylmethyl-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

10 4-[3-(2-Ethoxy-ethoxymethyl)-2-ethyl-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Bromo-phenyl)-4-(2-ethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-phenylamino)-2-phenyl-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

15 4-(2-Ethyl-3-hydroxymethyl-phenylamino)-2-phenyl-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Chloro-phenyl)-4-(2-ethyl-3-hydroxymethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Chloro-phenyl)-4-(2-ethyl-3-imidazol-1-ylmethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

20 4-(2-Ethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide
or a pharmaceutically acceptable salt thereof.

7. A compound of formula (I) as defined in any one of claims 1 to 6 for use in therapy


25 8. A pharmaceutical composition comprising a compound of formula (I) or a
pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable
carrier.

9. A method of treating a disease or condition mediate by JAK3 which comprises administering to a patient in need of such treatment a compound of formula (I) as defined in claims 1 to 6 or a pharmaceutically acceptable salt thereof.

5 10. A method according to claim 9 in which the disease or condition is asthma, host versus graft rejection/transplantation or rheumatoid arthritis.

11. A process for the preparation of a compound of formula (I) which comprises: reaction of a compound of formula (II):

10



(II)

15 in which R¹ is as defined in formula (I) or is a protected derivatives thereof and L is a leaving group, with a compound of formula (III):

Ar-NH₂ (III)

20 in which Ar is as defined in formula (I) or is a protected derivatives thereof, and optionally thereafter:

- removing any protecting groups
- converting a compound of formula (I) into a further compound of formula (I)
- forming a pharmaceutically acceptable salt.

25